Photo from archive.org
Inhaled corticosteroid/formoterol (ICS/FOR) combination medications were initially developed as maintenance therapy; more recently they are also used as relievers in Europe and this use is proposed in the USA. ICS… Click to show full abstract
Inhaled corticosteroid/formoterol (ICS/FOR) combination medications were initially developed as maintenance therapy; more recently they are also used as relievers in Europe and this use is proposed in the USA. ICS coupled with FOR (a long-acting β2-agonist) is recommended by the 2020 Global Initiative for Asthma (GINA) guidelines [1] for steps 2–5 as maintenance and reliever (SMART) and is recommended for steps 3 and 4 in the 2020 USA National Asthma Education and Prevention Program (NAEPP) [2]. While SMART has regulatory approval in Europe, it does not in the USA. Prescribers and asthma patients should know that ICS/LABA combination inhalers used as reliever therapy may expire under patient use sooner than the expiration shown on the inhaler, compromising effectiveness if not considered by the prescriber and patient https://bit.ly/3fhHMX2
Journal Title: European Respiratory Journal
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!